Broth Microdilution and Time-Kill Testing of Caspofungin, Voriconazole, Amphotericin B and their Combinations Against Clinical Isolates of Candida krusei

被引:6
|
作者
Oz, Yasemin [1 ]
Dag, Ilknur [2 ]
Kiraz, Nuri [3 ]
机构
[1] Eskisehir Osmangazi Univ, Fac Med, Dept Microbiol, Div Mycol, Eskisehir, Turkey
[2] Eskisehir Osmangazi Univ, Hlth Serv Vocat High Sch, Eskisehir, Turkey
[3] Istanbul Univ, Cerrahpasa Med Fac, Dept Microbiol, Div Mycol, Istanbul, Turkey
关键词
Candida krusei; Caspofungin; Voriconazole; Amphotericin B; Combination; Time-kill; IN-VITRO; DISK DIFFUSION; PHARMACODYNAMIC CHARACTERISTICS; INVASIVE CANDIDIASIS; ANTIFUNGAL AGENTS; FLUCONAZOLE; GLABRATA; SUSCEPTIBILITY; PROPOSAL; TRENDS;
D O I
10.1007/s11046-011-9459-x
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Treatment of invasive Candida krusei infections can be difficult due to its intrinsic fluconazole resistance and its reduced susceptibility to amphotericin B and flucytosine. Caspofungin (CAS) acts on a different cellular target, and its combination with voriconazole (VOR) or amphotericin B (AmB) appears promising. We evaluated the activity of CAS, VOR and AmB alone and in combination at 1/4, 1, 4xMIC concentrations by time-kill method against 30 C. krusei isolates. All isolates were susceptible to CAS and VOR; AmB MICs were 2 mu g/ml for 50% of isolates by broth microdilution. CAS showed a fast killing activity at all concentrations; it was fungistatic at 1/4xMICs and fungicidal at 1-4xMICs in general. VOR displayed a concentration-independent fungistatic activity against all isolates. AmB exhibited a concentration-dependent activity; it was fungistatic at 1/4-1xMIC and fungicidal at 4xMIC. The most common interaction was indifference for both combinations. Frequency of synergic interaction for the VOR + CAS combination was 66.7% at 1/4xMIC after 48 h. The best results for CAS + AmB combination were obtained at 4xMIC in the first 4-8 h; synergic interaction was detected for 20 isolates (66.7%) at 4xMIC after 4 h. Consequently, VOR and CAS alone have been found effective, and high AmB MICs are remarkable against clinical C. krusei isolates in vitro. The combinations of CAS with VOR or AmB have exhibited promising results.
引用
收藏
页码:27 / 34
页数:8
相关论文
共 50 条
  • [31] Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments
    Clancy, Cornelius J.
    Huang, Hong
    Cheng, Shaoji
    Derendorf, Hartmut
    Nguyen, M. Hong
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (07) : 2569 - 2572
  • [32] In vitro activity of voriconazole and amphotericin B against Candida albicans, Candida krusei, and Cryptococcus neoformans in human cerebrospinal fluid
    al Jalali, Valentin
    Sauermann, Robert
    Eberl, Sabine
    Zeitlinger, Markus
    INFECTION, 2019, 47 (04) : 565 - 570
  • [33] In vitro activity of voriconazole and amphotericin B against Candida albicans, Candida krusei, and Cryptococcus neoformans in human cerebrospinal fluid
    Valentin al Jalali
    Robert Sauermann
    Sabine Eberl
    Markus Zeitlinger
    Infection, 2019, 47 : 565 - 570
  • [34] Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi
    Diekema, DJ
    Messer, SA
    Hollis, RJ
    Jones, RN
    Pfaller, MA
    JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (08) : 3623 - 3626
  • [35] Post-antifungal effects and time-kill studies of anidulafungin, caspofungin, and micafungin against Candida glabrata and Candida parapsilosis
    Smith, Raymond P.
    Baltch, Aldona
    Bopp, Lawrence H.
    Ritz, William J.
    Michelsen, Phyllis P.
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2011, 71 (02) : 131 - 138
  • [36] Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates
    Pfaller, MA
    Messer, SA
    Boyken, L
    Rice, C
    Tendolkar, S
    Hollis, RJ
    Diekema, DJ
    JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (07) : 3117 - 3119
  • [37] Time-kill assays of amphotericin B plus anidulafungin against Candida tropicalis biofilms formed on two different biomaterials
    Fernandez-Rivero, Marcelo E.
    del Pozo, Jose L.
    Ramirez, Paula
    Valentin, Eulogio
    Ruiz-Gaitan, Alba
    Peman, Javier
    Canton, Emilia
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2018, 41 (01): : 23 - 27
  • [38] In vivo efficacy of amphotericin B, fluconazole, voriconazole and caspofungin against Candida orthopsilosis in a neutropenic mouse model
    Majoros, L.
    Szilagyi, J.
    Bayegan, S.
    Tavanti, A.
    Kemeny-Beke, A.
    Kardos, G.
    Adnan, A.
    Gesztely, R.
    MYCOSES, 2009, 52 : 121 - 121
  • [39] In Vitro Fungicidal Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata, Candida bracarensis, and Candida nivariensis Evaluated by Time-Kill Studies
    Gil-Alonso, Sandra
    Jauregizar, Nerea
    Canton, Emilia
    Eraso, Elena
    Quindos, Guillermo
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (06) : 3615 - 3618
  • [40] In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies
    Di Bonaventura, G
    Spedicato, I
    Picciani, C
    D'Antonio, D
    Piccolomini, R
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (11) : 4453 - 4456